Only one RCT61 compared the LBR between the GnRH antagonist and GnRH agonist protocols in 74 PCOS women, and it did not report any significant differences in LBR between the GnRH antagonist protocol and the Long GnRH agonist protocol (RR = 0.78, 95% CI: [0.46 to 1.32]; P = 0.35; low-quality evidence; Fig. 2). This evidence concerns the gene GNRH1 and polycystic ovary syndrome.